dcsimg Aranesp® (darbepoetin alfa) – Efficacy for Patients on Dialysis
› Email› Print

Aranesp® has proven efficacy in patients on dialysis

Aranesp® provides sustained efficacy at
extended dosing intervals1

Aranesp® effectively maintained mean Hb levels for patients on dialysis

Hb levels were maintained with Aranesp® QW and Q2W dosing1,2

Hb levels were maintained with Aranesp® QW and Q2W dosing

Individualize Aranesp® QW and Q2W dosing to support erythropoiesis and intervene to address Hb changes3,4

Important Safety Information

  • Patients with CKD and an insufficient hemoglobin response to ESA therapy may be at even greater risk for cardiovascular reactions and mortality than other patients. A rate of hemoglobin rise of > 1 g/dL over 2 weeks may contribute to these risks.
  • In controlled clinical trials, ESAs increased the risk of death in patients undergoing coronary artery bypass graft surgery (CABG) and the risk of deep venous thrombosis (DVT) in patients undergoing orthopedic procedures.

Scroll down for additional
Important Safety Information.

Abbreviations and References:
BIW = twice weekly; CKD = chronic kidney disease; Hb = hemoglobin; mITT = modified intent-to-treat patients who enrolled in the study and received at least 1 dose of study drug; QW = once weekly; Q2W = once every 2 weeks; TIW = three times weekly.
References: 1. Vanrenterghem Y, Bárány P, Mann JFE, et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int. 2002;62(6):2167-2175. 2. Nissenson AR, Swan SK, Lindberg JS, et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis. 2002;40(1):110-118. 3. Aranesp® (darbepoetin alfa) prescribing information, Amgen. 4. Khan I, Krishnan M, Kothawala A, Ashfaq A. Association of dialysis facility-level hemoglobin measurement and erythropoiesis-stimulating agent dose adjustment frequencies with dialysis facility-level hemoglobin variation: a retrospective analysis. BMC Nephrol. 2011;12:22.

Biotechnology by Amgen®